糖尿病大血管并发症相关动物模型的构建与应用进展
杨玉洁 , 张莉莉 , 潘昕昀 , 丁英鹏 , 王中群
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (8) : 1127 -1134.
糖尿病大血管并发症相关动物模型的构建与应用进展
Advances in the construction and application of animal models for diabetic macrovascular complications
糖尿病大血管并发症是糖尿病患者致残和死亡的主要原因,其核心病理特征在于长期代谢紊乱背景下动脉粥样硬化的加速进展及斑块不稳定性增加。动物模型在阐明糖尿病大血管并发症的发病机制及评价防治措施中具有重要作用。本文围绕糖尿病冠状动脉疾病、脑血管病变及外周动脉疾病等主要类型,对饮食诱导、化学诱导、基因修饰及联合干预等常用动物模型的构建方法、病理特征及应用现状进行综述,比较不同模型在模拟疾病表型和研究适用性方面的差异,并分析其局限性。旨在为糖尿病大血管并发症动物模型的合理选择与改进提供参考依据。
Diabetes-associated macrovascular complications constitute a principal source of disability and mortality among individuals with diabetes. The defining pathological hallmark of these complications is the accelerated development of atherosclerosis accompanied by heightened plaque instability, arising in the context of chronic metabolic dysregulation. Animal models are therefore indispensable for elucidating the underlying mechanisms of diabetic macrovascular disease and for rigorously assessing preventive and therapeutic interventions. This review concentrates on the major manifestations of diabetic macrovascular pathology, including coronary artery disease, cerebrovascular disease, and peripheral arterial disease. It provides a systematic synthesis of the construction strategies, pathological features, and current research applications of widely used animal models, encompassing diet-induced, chemically induced, genetically modified, and combined-intervention approaches. In addition, the review offers a comparative evaluation of these models with respect to their capacity to recapitulate disease phenotypes and their suitability for addressing specific research questions, while also critically examining their methodological limitations. Collectively, this work aims to inform the rational selection and refinement of animal models for the study of diabetic macrovascular complications.
| [1] |
GBD 2021 Diabetes Collaborators. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021[J].Lancet, 2023, 402(10397): 203-234. |
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
|
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
|
| [16] |
|
| [17] |
Xiong L, Diwakarla S, Chatzis R, |
| [18] |
Zhang Z, Xu Y, Pang K, |
| [19] |
|
| [20] |
|
| [21] |
Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes[J].Diabetologia, 2008, 51(2): 216-226. |
| [22] |
|
| [23] |
|
| [24] |
|
| [25] |
|
| [26] |
|
| [27] |
|
| [28] |
|
| [29] |
|
| [30] |
|
| [31] |
|
| [32] |
|
| [33] |
|
| [34] |
|
| [35] |
|
| [36] |
|
| [37] |
|
| [38] |
|
| [39] |
|
| [40] |
|
| [41] |
|
| [42] |
|
| [43] |
|
| [44] |
|
| [45] |
|
| [46] |
|
| [47] |
|
| [48] |
|
| [49] |
|
| [50] |
|
| [51] |
|
| [52] |
|
| [53] |
|
| [54] |
|
| [55] |
Sharma S, Cheema M, |
| [56] |
|
| [57] |
|
| [58] |
|
| [59] |
|
| [60] |
|
| [61] |
|
| [62] |
|
| [63] |
|
| [64] |
|
| [65] |
|
| [66] |
|
| [67] |
|
| [68] |
|
国家自然科学基金(82370457)
江苏省重点研发计划(BE2022780)
/
| 〈 |
|
〉 |